Literature DB >> 8256197

Carbohydrate immunity in American trypanosomiasis.

L R Travassos1, I C Almeida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8256197     DOI： 10.1007/bf00201100

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  89 in total

1.  Glycoproteins from trypanosoma cruzi: partial purification by gel chromatography.

Authors:  M J Alves; W Colli
Journal:  FEBS Lett       Date:  1975-04-01       Impact factor: 4.124

2.  Evasion of Trypanosoma cruzi from complement lysis.

Authors:  T L Kipnis; W D da Silva
Journal:  Braz J Med Biol Res       Date:  1989       Impact factor: 2.590

3.  An 85-kilodalton surface antigen gene family of Trypanosoma cruzi encodes polypeptides homologous to bacterial neuraminidases.

Authors:  G B Takle; G A Cross
Journal:  Mol Biochem Parasitol       Date:  1991-10       Impact factor: 1.759

4.  A family of glycoinositol phospholipids from Leishmania major. Isolation, characterization, and antigenicity.

Authors:  M J McConville; A Bacic
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

5.  Trypanosoma cruzi: amastigotes and trypomastigotes interact with different structures on the surface of HeLa cells.

Authors:  R A Mortara
Journal:  Exp Parasitol       Date:  1991-07       Impact factor: 2.011

Review 6.  Anti-alpha-galactosyl antibodies in chagasic patients. Possible biological significance.

Authors:  S R Milani; L R Travassos
Journal:  Braz J Med Biol Res       Date:  1988       Impact factor: 2.590

7.  A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells.

Authors:  S Schenkman; M S Jiang; G W Hart; V Nussenzweig
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

8.  Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies.

Authors:  I C Almeida; S R Milani; P A Gorin; L R Travassos
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

9.  Incorporation of sialic acid into Trypanosoma cruzi macromolecules. A proposal for a new metabolic route.

Authors:  J O Previato; A F Andrade; M C Pessolani; L Mendonça-Previato
Journal:  Mol Biochem Parasitol       Date:  1985-06       Impact factor: 1.759

10.  In vivo incorporation of palmitic acid and galactose in glycolipids of Trypanosoma cruzi epimastigotes.

Authors:  R M de Lederkremer; B Zingales; A N Confalonieri; A S Couto; N F Martin; W Colli
Journal:  Biochem Int       Date:  1985-01
View more
  10 in total

1.  Specificity and prevalence of natural bovine anti-alpha galactosyl (Galalpha1-6Glc or Galalpha1-6Gal) antibodies.

Authors:  Y Ni; R Powell; D D Turner; I Tizard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Reactivity of chagasic antigal antibodies with noninfected cells treated with Trypanosoma cruzi secreted/excreted antigens.

Authors:  J K Yokoyama-Yasunaka; R M Piazza; E S Umezawa; A M Stolf
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

3.  Reversed Immunoglycomics Identifies α-Galactosyl-Bearing Glycotopes Specific for Leishmania major Infection.

Authors:  Alba L Montoya; Victoria M Austin; Susana Portillo; Irodiel Vinales; Roger A Ashmus; Igor Estevao; Sohan R Jankuru; Yasser Alraey; Waleed S Al-Salem; Álvaro Acosta-Serrano; Igor C Almeida; Katja Michael
Journal:  JACS Au       Date:  2021-07-12

4.  Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease.

Authors:  Nathaniel S Schocker; Susana Portillo; Carlos R N Brito; Alexandre F Marques; Igor C Almeida; Katja Michael
Journal:  Glycobiology       Date:  2015-09-18       Impact factor: 4.313

5.  Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi.

Authors:  I C Almeida; M A Ferguson; S Schenkman; L R Travassos
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

Review 6.  Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.

Authors:  Uri Galili
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

7.  New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia.

Authors:  Cristina Alonso-Vega; Julio A Urbina; Sergi Sanz; María-Jesús Pinazo; Jimy José Pinto; Virginia R Gonzalez; Gimena Rojas; Lourdes Ortiz; Wilson Garcia; Daniel Lozano; Dolors Soy; Rosa A Maldonado; Rana Nagarkatti; Alain Debrabant; Alejandro Schijman; M Carmen Thomas; Manuel Carlos López; Katja Michael; Isabela Ribeiro; Joaquim Gascon; Faustino Torrico; Igor C Almeida
Journal:  BMJ Open       Date:  2021-12-31       Impact factor: 2.692

8.  Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins.

Authors:  Sayonara M Viana; Alba L Montoya; Augusto M Carvalho; Brunele S de Mendonça; Susana Portillo; Janet J Olivas; Nasim H Karimi; Igor L Estevao; Uriel Ortega-Rodriguez; Edgar M Carvalho; Walderez O Dutra; Rosa A Maldonaldo; Katja Michael; Camila I de Oliveira; Igor C Almeida
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

9.  Evaluation of a chemiluminescent enzyme-linked immunosorbent assay for the diagnosis of Trypanosoma cruzi infection in a nonendemic setting.

Authors:  Luis Izquierdo; Alexandre Ferreira Marques; Montserrat Gállego; Sílvia Sanz; Sílvia Tebar; Cristina Riera; Llorenç Quintó; Edelweiss Aldasoro; Igor C Almeida; Joaquim Gascon
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

10.  Specific Recognition of β-Galactofuranose-Containing Glycans of Synthetic Neoglycoproteins by Sera of Chronic Chagas Disease Patients.

Authors:  Alba L Montoya; Eileni R Gil; Emily L Heydemann; Igor L Estevao; Bianca E Luna; Cameron C Ellis; Sohan R Jankuru; Belkisyolé Alarcón de Noya; Oscar Noya; Maria Paola Zago; Igor C Almeida; Katja Michael
Journal:  Molecules       Date:  2022-01-09       Impact factor: 4.927
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.